SOLENO THERAPEUTICS 8-K: Leadership & Compensation Changes Reported

TL;DR

**SOLENO THERAPEUTICS filed an 8-K on Jan 30, 2024, reporting executive changes and compensation arrangements from Jan 24, 2024.**

AI Summary

SOLENO THERAPEUTICS INC filed an 8-K on January 30, 2024, reporting an event that occurred on January 24, 2024. This filing indicates changes related to the departure or election of directors or officers and their compensatory arrangements, as well as financial statements and exhibits. While the specific details of the personnel changes or compensation are not provided in this summary, such events can signal shifts in company strategy or leadership stability, which could impact investor confidence and the stock's future direction.

Why It Matters

Changes in leadership or executive compensation can signal strategic shifts or financial health, directly influencing investor perception and the company's operational trajectory.

Risk Assessment

Risk Level: medium — The filing indicates changes in leadership and compensation, which can introduce uncertainty regarding future company direction and stability, warranting a medium risk assessment.

Analyst Insight

A smart investor would monitor subsequent filings or press releases from SOLENO THERAPEUTICS INC for specific details regarding the personnel changes and compensatory arrangements, as these specifics will determine the actual impact on the company's strategy and financial outlook.

Key Players & Entities

• SOLENO THERAPEUTICS INC (company) — registrant
• January 24, 2024 (date) — date of earliest event reported
• January 30, 2024 (date) — filing date of the 8-K
• Delaware (company) — state of incorporation
• 001-36593 (company) — Commission File No.
• 77-0523891 (company) — IRS Employer Identification Number
• 203 Redwood Shores Pkwy, Suite 500, Redwood City, CA 94065 (company) — principal executive offices address
• 650-213-8444 (company) — registrant's telephone number
• SLNO (company) — trading symbol
• NASDAQ (company) — exchange on which registered

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value SLNO NASDAQ Indicate by

Filing Documents

• d721921d8k.htm (8-K) — 26KB
• d721921dex101.htm (EX-10.1) — 76KB
• 0001193125-24-019500.txt ( ) — 242KB
• slno-20240124.xsd (EX-101.SCH) — 3KB
• slno-20240124_lab.xml (EX-101.LAB) — 18KB
• slno-20240124_pre.xml (EX-101.PRE) — 11KB
• d721921d8k_htm.xml (XML) — 4KB

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 24, 2024, the Board of Directors of Soleno Therapeutics, Inc. (the "Company") amended the 2020 Inducement Equity Incentive Plan (the "Inducement Plan") to reserve an additional 500,000 shares of the Company's common stock (the "Additional Shares") for issuance pursuant to equity awards granted under the Inducement Plan. The amendment to the Inducement Plan was adopted without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The Inducement Plan provides for the grant of equity-based awards, including nonstatutory stock options, restricted stock units, restricted stock, stock appreciation rights, performance shares and performance units, and its terms are substantially similar to the Company's 2014 Equity Incentive Plan, including with respect to treatment of equity awards in the event of a "merger" or "change in control" as defined under the Inducement Plan, but with such other terms and conditions intended to comply with the Nasdaq Inducement Award exception. Awards under the Inducement Plan may only be made to individuals not previously employees or non-employee directors of the Company (or following such individuals' bona fide period of non-employment with the Company), as an inducement material to the individuals' entry into employment with the Company or in connection with a merger or acquisition, to the extent permitted by the Nasdaq Listing Rules. The foregoing description of the Inducement Plan, as amended, is a summary only and is qualified in its entirety by the full text of the Inducement Plan, as amended, a copy of which is filed herewith as Exhibit 10.1.

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 10.1 2020 Inducement Equity Incentive Plan, as amended on January 24, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SOLENO THERAPEUTICS, INC. Date: January 30, 2024 By: /s/ Anish Bhatnagar Anish Bhatnagar Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR